IP Library Patent Application 11005897
Patent Application
App. No. 11/005,897

Inhibition of pathogens by probiotic bacteria

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/005,897
Abstract

Compositions containing a lactic acid-producing bacterial strain, e.g., Bacillus coagulans for inhibition of pathogenic bacterial infections. Spores or extracellular products produced by the bacterial strains are also useful as inhibitory agents.

Claims (26)

1 . A composition comprising an isolated Bacillus strain, wherein said strain (a) produces lactic acid, (b) has an optimal growth temperature of in the range of 20-44° C., and (c) grows in a pH range of 2-5.

2 . The composition of claim 1 , wherein said strain produces L(+) dextrorotatory lactic acid and produces spores resistant to temperatures of up to approximately 90° C.

3 . The composition of claim 1 , wherein said strain is selected from the group consisting of Bacillus coagulaus, Bacillus stereothermophilus, Bacillus thermoacidurans, Lactobacillus sporogenes, Bacillus smithii, Bacillus dextrolacticus, Lactobacillus cereale , and Bacillus recemilacticus.

4 . The composition of claim 1 , wherein said strain is Bacillus coagulans.

5 . The composition of claim 1 , wherein said strain is selected from the group consisting of Bacillus coagulans GBI-1, Bacillus coagulans GBI-20, Bacillus coagulans GBI-30 and Bacillus coagulans GBI-40.

6 . (canceled)

7 . A composition comprising an isolated Bacillus strain, wherein said strain produces lactic acid and has an optimal growth temperature of in the range of 20-25° C.

8 . The composition of claim 7 , wherein said strain produces L(+) dextrorotatory lactic acid and produces spores resistant to temperatures of up to approximately 90° C.

9 . The composition of claim 7 , wherein said strain is selected from the group consisting of Bacillus coagulans, Bacillus stereothermophilus, Bacillus thermoacidurans, Lactobacillus sporogenes, Bacillus smithii, Bacillus dextrolacticus, Lactobacillus cereale , and Bacillus recemilacticus.

10 . The composition of claim 7 , wherein said strain is Bacillus coagulans.

11 . The composition of claim 7 , wherein said strain is Bacillus coagulans GBI-20.

12 . (canceled)

13 . A composition comprising an isolated Bacillus strain, wherein said strain produces lactic acid and has an optimal growth temperature of in the range of 25-35° C.

14 . The composition of claim 13 , wherein said strain produces L(+) dextrorotatory lactic acid and produces spores resistant to temperatures of up to approximately 90° C.

15 . The composition of claim 13 , wherein said strain is selected from the group consisting of Bacillus coagulans, Bacillus stereothermophilus, Bacillus thermoacidurans, Lactobacillus sporogenes, Bacillus smithii, Bacillus dextrolacticus, Lactobacillus cereale , and Bacillus recemilacticus.

16 . The composition of claim 13 , wherein said strain is Bacillus coagulans.

17 - 18 . (canceled)

19 . A composition comprising an isolated Bacillus strain, wherein said strain produces lactic acid and has an optimal growth temperature of in the range of 35-40° C.

20 . The composition of claim 19 , wherein said strain produces L(+) dextrorotatory lactic acid and produces spores resistant to temperatures of up to approximately 90° C.

21 . The composition of claim 19 , wherein said strain is selected from the group consisting of Bacillus coagulans, Bacillus stereothermophilus, Bacillus thermoacidurans, Lactobacillus sporogenes, Bacillus smithii, Bacillus dextrolacticus, Lactobacillus cereale , and Bacillus recemilacticus.

22 . The composition of claim 19 , wherein said strain is Bacillus coagulans.

23 . (canceled)

24 . An extracellular product derived from the composition of claim 19 .

25 . A method of inhibiting a pathogenic bacterial infection, comprising contacting an infected site with the composition of claim 1 .

26 . A method of inhibiting a pathogenic bacterial infection, comprising contacting an infected site with a Bacillus coagulans composition.

27 - 35 . (canceled)

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Sep 12, 2017
From: SILICON VALLEY BANK
To: GANEDEN BIOTECH, INC.
Reel/Frame 043822/0897 →
SECURITY AGREEMENT Recorded Oct 10, 2012
From: GANEDEN BIOTECH, INC.
To: SILICON VALLEY BANK
Reel/Frame 029103/0202 →
LICENSE Recorded Jul 19, 2011
From: GANEDEN BIOTECH, INC.
To: SCHIFF NUTRITION GROUP, INC.
Reel/Frame 026616/0128 →
SECURITY AGREEMENT Recorded Jul 19, 2011
From: GANEDEN BIOTECH, INC.
To: SCHIFF NUTRITION GROUP, INC.
Reel/Frame 026616/0950 →